Last reviewed · How we verify
Fulvestrant injection — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
Fulvestrant injection (fulvestrant-injection) — Pfizer Inc.. Fulvestrant binds to estrogen receptors in breast cancer cells, leading to their degradation and inhibiting tumor growth.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fulvestrant injection TARGET | fulvestrant-injection | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fulvestrant injection CI watch — RSS
- Fulvestrant injection CI watch — Atom
- Fulvestrant injection CI watch — JSON
- Fulvestrant injection alone — RSS
Cite this brief
Drug Landscape (2026). Fulvestrant injection — Competitive Intelligence Brief. https://druglandscape.com/ci/fulvestrant-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing